• DOMENICA 20 GIUGNO 2021 - Madonna della Consolazione

Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility

ATTENZIONE
Tutto il materiale presente in questo articolo è coperto da Copyright Adnkronos.com e ne è vietata la riproduzione, anche parziale.


GAITHERSBURG, Md., May 6, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has finalized an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi) for supply of its recombinant protein-based COVID-19 vaccine candidate to the COVAX Facility. Under the APA, Novavax is expected to manufacture and distribute 350 million doses of NVX-CoV2373 to countries participating under the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. Under a separate purchase agreement with Gavi, the Serum Institute of India (Serum Institute) is expected to manufacture and deliver the balance of the 1.1 billion doses of Novavax' vaccine.



Sannioportale.it